Family Intervention for Mental Illness and Substance Abuse

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00043693
First received: August 12, 2002
Last updated: August 7, 2012
Last verified: August 2012
  Purpose

This study will evaluate a family intervention program for individuals with bipolar disorder, schizophrenia, or schizoaffective disorder and co-occurring substance use disorders.


Condition Intervention
Schizophrenia
Bipolar Disorder
Substance-related Disorders
Behavioral: Family Intervention for Dual Diagnosis
Behavioral: Family psychoeducation program

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Family Intervention for SMI and Substance Use Disorder

Resource links provided by NLM:


Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Alcohol use scale-revised [ Time Frame: Measured at baseline, during treatment, and post-treatment ] [ Designated as safety issue: No ]
  • Drug use scale-revised [ Time Frame: Measured at baseline, during treatment, and post-treatment ] [ Designated as safety issue: No ]
  • Substance abuse treatment scale [ Time Frame: Measured at baseline, during treatment, and post-treatment ] [ Designated as safety issue: No ]
  • Timeline followback calandar [ Time Frame: Measured at baseline, during treatment, and post-treatment ] [ Designated as safety issue: No ]

Enrollment: 108
Study Start Date: April 2002
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
Behavioral: Family Intervention for Dual Diagnosis
The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
Active Comparator: 2
Participants will be placed in a family psychoeducation program.
Behavioral: Family psychoeducation program
The family psychoeducation program consists of 6 weekly sessions.

Detailed Description:

Substance use disorder (SUD) in persons with severe mental illness may worsen the course of psychiatric illness. The loss of family support for individuals with mental illness is a major contributing factor to housing instability, homelessness, and other problems. Despite progress toward integrating mental health and substance abuse services, interventions that improve the course of mental illness while helping the families of the mentally ill are not currently available. Enhancing skills for coping with mental illness may be an effective strategy for treating SUD, decreasing caregiver burden, and improving the long-term outcomes for people with mental illness.

Patients and their families are randomly assigned to either the Family Intervention for Dual Diagnosis (FIDD) program or family psychoeducation. The FIDD program lasts for up to 3 years and includes both single and multiple-family group formats. The family psychoeducation program consists of 6 weekly sessions. Routine assessments are conducted on all patients, and relatives are evaluated on a wide range of outcomes, including substance abuse, hospitalizations, psychiatric symptoms, legal problems, aggression, housing and homelessness, family burden, social support, and quality of life. To determine the effectiveness of the FIDD program, knowledge of mental illness and problem-solving skills are assessed in the families following treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have schizophrenia, schizoaffective disorder, or bipolar disorder
  • Have a current substance use disorder (within the past 6 months)
  • Are willing to have at least 4 hours of contact per week with family members or significant others
  • Plan to remain in the community
  • Have family members or significant others who consent to participate in the study and plan to remain in the community
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00043693

Locations
United States, California
Pacific Clinics El Camino
Santa Fe Springs, California, United States, 90670-3691
United States, Massachusetts
North Suffolk Mental Health Association
Chelsea, Massachusetts, United States, 02150
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Investigators
Principal Investigator: Kim T. Mueser, PhD Dartmouth-Hitchcock Medical Center
Principal Investigator: Shirley Glynn, PhD University of California, Los Angeles
  More Information

Publications:
Responsible Party: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT00043693     History of Changes
Other Study ID Numbers: R01 MH62629, R01MH062629, DSIR SE-CE
Study First Received: August 12, 2002
Last Updated: August 7, 2012
Health Authority: United States: Federal Government

Keywords provided by Dartmouth-Hitchcock Medical Center:
Psychotic Disorders
Schizoaffective Disorder
Substance Abuse

Additional relevant MeSH terms:
Bipolar Disorder
Disease
Schizophrenia
Substance-Related Disorders
Affective Disorders, Psychotic
Chemically-Induced Disorders
Mental Disorders
Mood Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on October 21, 2014